Bernhard K. Keppler

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

Robert Trondl, Petra Heffeter, Christian R. Kowol et al. · Chemical Science · 2014 · 659 citations · Full text

Medicine, Oncology, Pharmacology +14

Gold(III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action

Angela Casini, Christian G. Hartinger, Chiara Gabbiani et al. · Journal of Inorganic Biochemistry · 2007 · 266 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

Frederike Lentz, Anne Drescher, Andreas Lindauer et al. · Anti-Cancer Drugs · 2009 · 237 citations

Medicine, Pharmacokinetics, Pharmacology +10

Redox behavior of tumor-inhibiting ruthenium(<scp>iii</scp>) complexes and effects of physiological reductants on their binding to GMP

Petra Schluga, Christian G. Hartinger, Alexander Egger et al. · Dalton Transactions · 2006 · 218 citations · Full text

Natural Sciences, Medicinal Chemistry, Pharmacology +16

Structure−Activity Relationships for NAMI-A-type Complexes (HL)[<i>trans</i>-RuCl₄L(<i>S</i>-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole):  Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity

Michael Groessl, Erwin Reisner, Christian G. Hartinger et al. · Journal of Medicinal Chemistry · 2007 · 213 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17